Objective: to compare the efficacy and tolerability of Buserelin-long PhC and those of other luteinizing hormone-releasing hormone (LHRH) analogs. Subjects and methods. Sixty-two prostate cancer patients treated with LHRH analogs were followed up. Group 1 received therapy with Buserelin-long PhC; Group 2 had other LHRH analogs. Results. The use of Buserelin-long PhC results in reductions in the level of testosterone to the postcastration one, in that of PSA, in the volume of prostate and in the symptoms of urination problems in the absence of serious side effects. Conclusion. Along with expensive foreign medicines, such as goserelin, triptorelin and leuprorelin, Buserelin-long PhS showed high efficacy and tolerability in the treatment of hormone-dependent prostate cancer.